2024
Procedure Volume and Outcomes With WATCHMAN Left Atrial Appendage Occlusion
Friedman D, Du C, Zimmerman S, Tan Z, Lin Z, Vemulapalli S, Kosinski A, Piccini J, Pereira L, Minges K, Faridi K, Masoudi F, Curtis J, Freeman J. Procedure Volume and Outcomes With WATCHMAN Left Atrial Appendage Occlusion. Circulation Cardiovascular Interventions 2024, 17: e013466. PMID: 38889251, PMCID: PMC11189610, DOI: 10.1161/circinterventions.123.013466.Peer-Reviewed Original ResearchConceptsVolume-outcome relationshipLikelihood of procedural successLeft atrial appendage occlusionProcedural successProcedure volumeAppendage occlusionNational Cardiovascular Data Registry LAAO RegistryVolume quartilesLeft atrial appendage occlusion devicesThree-level hierarchical generalized linear modelsMinimum volume thresholdsWatchman FLX deviceProcedural success rateHierarchical generalized linear modelsAssociated with outcomePhysician volumeWATCHMAN procedureFLX deviceOcclusion deviceVolume thresholdCardiovascular proceduresPhysiciansHospitalNational analysisSuccess rate
2021
Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathy
Higgins AY, Annapureddy AR, Wang Y, Minges KE, Bellumkonda L, Lampert R, Rosenfeld LE, Jacoby DL, Curtis JP, Miller EJ, Freeman JV. Risk and predictors of mortality after implantable cardioverter-defibrillator implantation in patients with sarcoid cardiomyopathy. American Heart Journal 2021, 246: 21-31. PMID: 34968442, DOI: 10.1016/j.ahj.2021.12.011.Peer-Reviewed Original ResearchConceptsNon-ischemic cardiomyopathyAtrial fibrillation/flutterChronic lung diseaseCardiac sarcoidosisHeart failureCS patientsNICM patientsICD implantationLung diseaseNew York Heart Association class III heart failureNational Cardiovascular Data Registry ICD RegistryNYHA class IV heart failureClass III heart failureClass IV heart failureImplantable cardioverter defibrillator implantationKaplan-Meier survival curvesCox proportional hazards modelPredictors of mortalityCardioverter-defibrillator implantationVentricular ejection fractionMultivariable logistic regressionPrior ventricular arrhythmiasProportional hazards modelRate of deathTime of implantationSex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion
Darden D, Duong T, Du C, Munir MB, Han FT, Reeves R, Saw J, Zeitler EP, Al-Khatib SM, Russo AM, Minges KE, Curtis JP, Freeman JV, Hsu JC. Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion. JAMA Cardiology 2021, 6: 1275-1284. PMID: 34379072, PMCID: PMC8358791, DOI: 10.1001/jamacardio.2021.3021.Peer-Reviewed Original ResearchConceptsHospital adverse eventsMajor adverse eventsAdverse eventsAtrial appendage occlusionMajor bleedingPericardial effusionAppendage occlusionAtrial fibrillationSex differencesCongestive heart failureCoronary artery diseaseAdjusted logistic regression analysisParoxysmal atrial fibrillationLogistic regression analysisMultivariable adjusted logistic regression analysesPrior strokeUncontrolled hypertensionHospital outcomesHospital stayMultivariable adjustmentProlonged hospitalBaseline characteristicsCohort studySelect patientsArtery diseaseNational Trends in the Burden of Atrial Fibrillation During Hospital Admissions for Heart Failure
Reinhardt SW, Chouairi F, Miller PE, Clark KAA, Kay B, Fuery M, Guha A, Freeman JV, Ahmad T, Desai NR, Friedman DJ. National Trends in the Burden of Atrial Fibrillation During Hospital Admissions for Heart Failure. Journal Of The American Heart Association 2021, 10: e019412. PMID: 34013736, PMCID: PMC8483517, DOI: 10.1161/jaha.120.019412.Peer-Reviewed Original ResearchConceptsReduced ejection fractionComorbid atrial fibrillationHeart failureAtrial fibrillationEjection fractionHospital mortalityHF hospitalizationBackground Heart failureConclusion Atrial fibrillationWhite individualsNational Inpatient SampleMedian hospital chargesMore comorbiditiesComorbid hypertensionHF admissionsHF outcomesPatient demographicsDiabetes mellitusHospital admissionHospital chargesInpatient SampleVascular diseaseHospitalizationPatientsMortalityRelation of Cardiovascular Risk Factors to Mortality and Cardiovascular Events in Hospitalized Patients With Coronavirus Disease 2019 (from the Yale COVID-19 Cardiovascular Registry)
Pareek M, Singh A, Vadlamani L, Eder M, Pacor J, Park J, Ghazizadeh Z, Heard A, Cruz-Solbes AS, Nikooie R, Gier C, Ahmed ZV, Freeman JV, Meadows J, Smolderen KGE, Lampert R, Velazquez EJ, Ahmad T, Desai NR. Relation of Cardiovascular Risk Factors to Mortality and Cardiovascular Events in Hospitalized Patients With Coronavirus Disease 2019 (from the Yale COVID-19 Cardiovascular Registry). The American Journal Of Cardiology 2021, 146: 99-106. PMID: 33539857, PMCID: PMC7849530, DOI: 10.1016/j.amjcard.2021.01.029.Peer-Reviewed Original ResearchConceptsCardiovascular risk factorsCoronavirus disease 2019Risk factorsHigher troponin TCardiovascular diseaseCardiovascular eventsHospitalized patientsLaboratory findingsMental statusDisease 2019Multivariable binary logistic regression analysisTroponin TMajor adverse cardiovascular eventsPre-existing cardiovascular diseaseHigher C-reactive proteinCOVID-19 positive patientsPredictors of MACEPrevious ventricular arrhythmiaUse of P2YAdverse cardiovascular eventsProspective cohort studyTertiary care centerC-reactive proteinBinary logistic regression analysisPoor prognostic marker
2020
Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice
Sherwood MW, Piccini JP, Holmes DN, Pieper KS, Steinberg BA, Fonarow GC, Allen LA, Naccarelli GV, Kowey PR, Gersh BJ, Mahaffey KW, Singer DE, Ansell JE, Freeman JV, Chan PS, Reiffel JA, Blanco R, Peterson ED, Rao SV. Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice. Circulation Cardiovascular Interventions 2020, 13: e008274. PMID: 32408815, DOI: 10.1161/circinterventions.119.008274.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAnticoagulantsAtrial FibrillationCardiac CatheterizationDrug Administration ScheduleFactor Xa InhibitorsFemaleHemorrhageHumansMaleMiddle AgedPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsRegistriesRisk AssessmentRisk FactorsStrokeTime FactorsTreatment OutcomeUnited StatesWarfarinConceptsDirect-Acting Oral AnticoagulantsActing Oral AnticoagulantsOral anticoagulationCardiac catheterizationRadial artery accessAtrial fibrillationMajor bleedingOral anticoagulantsMedian ageArtery accessAtrial Fibrillation II registryPatients' median ageReal-world registryChronic kidney diseaseThird of patientsBetter Informed TreatmentManagement of patientsOAC typeAntiplatelet therapyDiabetes mellitusFemoral accessContemporary cohortOutcomes RegistryKidney diseaseMyocardial infarctionEnhanced electrocardiographic monitoring of patients with Coronavirus Disease 2019
Jain S, Workman V, Ganeshan R, Obasare ER, Burr A, DeBiasi RM, Freeman JV, Akar J, Lampert R, Rosenfeld LE. Enhanced electrocardiographic monitoring of patients with Coronavirus Disease 2019. Heart Rhythm 2020, 17: 1417-1422. PMID: 32387247, PMCID: PMC7200355, DOI: 10.1016/j.hrthm.2020.04.047.Peer-Reviewed Original ResearchConceptsQT prolongationCoronavirus disease 2019Electrocardiographic monitoringDisease 2019Pandemic coronavirus disease 2019QT-prolonging medicationsModifiable risk factorsIntensive care unitQT-prolonging drugsOngoing pandemic coronavirus disease 2019Assessment-Recommendation (SBAR) toolCOVID-19Electrophysiology serviceElectrolyte abnormalitiesCare unitUnique patientsPrimary teamRisk factorsPatientsPatient safetyECG monitoringProlongationRelevant interventionsTorsadesPointesFactors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation
Steinberg BA, Holmes DN, Pieper K, Allen LA, Chan PS, Ezekowitz MD, Freeman JV, Fonarow GC, Gersh BJ, Hylek EM, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J, Singer DE, Peterson ED, Piccini JP, Mendelson R, Nahhas A, Neutel J, Padanilam B, Pan D, Poock J, Raffetto J, Greengold R, Roan P, Saba F, Sackett M, Schneider R, Seymour Z, Shanes J, Shoemaker J, Simms V, Smiley N, Smith D, Snipes C, Sotolongo R, Staniloae C, Stoltz S, Suresh D, Tak T, Tannenbaum A, Turk S, Vora K, Randhawa P, Zebrack J, Silva E, Riley E, Weinstein D, Vasiliauskas T, Goldbarg S, Hayward D, Yarlagadda C, Laurion D, Osunkoya A, Burns R, Castor T, Spiller D, Luttman C, Anton S, McGarvey J, Guthrie R, Deriso G, Flood R, Fleischer L, Fierstein J, Aggarwal R, Jacobs G, Adjei N, Akyea-Djamson A, Alfieri A, Bacon J, Bedwell N, Berger P, Berry J, Bhagwat R, Bloom S, Boccalandro F, Capo J, Kapadia S, Casanova R, Morriss III J, Christensen T, Elsen J, Farsad R, Fox D, Frandsen B, Gelernt M, Gill S, Grubb S, Hall C, Harris H, Hotchkiss D, Ip J, Jaffrani N, Jones A, Kazmierski J, Waxman F, Kneller G, Labroo A, Jaffe B, Lebenthal M, Lee D, Lillestol M, LeClerc K, Maccaro P, Mayer N, Kozlowski J, Benjamin S, Detweiler R, Igic P, Jackson T, Pappas J, Littlefield R, Frey A, Vranian R, Long W, Grena P, Arouni A, Quinn J, Browne K, Forman S, Ebinger M, Blonder R, Snyder H, Slabic S, Williams D, Stein R, Kirkland S, Cohen K, Walthall W, Davis K, Snoddy B, Alvarado O, Leach C, Rothman S, Sharma A, Olatidoye A, AlMahameed S, Rosenthal S, Sutter G, Reiter W, Thompson T, Thew S, Kobayashi J, Williams M, Kramer J, Latif S, Rhee B, Adler A, Ruiz-Serrano D, Stringam S, Wolok K, Focil A, Butman S, Ingersoll H, Borge R, Al-Saghir Y, Coats P, Farris N, Shore K, Schwartz M, Gornick C, Eilat P, Quinlan E, Paliwal Y, Mitra R, Jingo A, Aslam A, Watson R, Voyce S, Turakhia M, Goytia-Leos D, Lurie M, Mallis G, Atwater B, Strobel J, Murray J, Fisher D, Atieh M, Landes R, Drabick A, Harman E, Ashcraft B, Krista M, Videlefsky A, Rivera Zayas E, Tan A. Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation. Circulation Arrhythmia And Electrophysiology 2020, 13: e007775. PMID: 32298144, PMCID: PMC7247417, DOI: 10.1161/circep.119.007775.Peer-Reviewed Original ResearchConceptsAntiarrhythmic drug useHRQoL improvementAtrial fibrillationPrior stroke/transient ischemic attackStroke/transient ischemic attackDrug useBaseline diastolic blood pressureChronic obstructive pulmonary diseaseAtrial Fibrillation EffectAF risk factorsTransient ischemic attackPeripheral arterial diseaseBetter Informed TreatmentDiastolic blood pressureHealth-related qualityObstructive pulmonary diseasePatient-reported outcomesQuality of lifeIschemic attackHigh-value careBlood pressurePulmonary diseaseArterial diseaseMultivariable analysisOutcomes RegistryPredictors of Cardiac Perforation With Catheter Ablation of Atrial Fibrillation
Friedman DJ, Pokorney SD, Ghanem A, Marcello S, Kalsekar I, Yadalam S, Akar JG, Freeman JV, Goldstein L, Khanna R, Piccini JP. Predictors of Cardiac Perforation With Catheter Ablation of Atrial Fibrillation. JACC Clinical Electrophysiology 2020, 6: 636-645. PMID: 32553212, DOI: 10.1016/j.jacep.2020.01.011.Peer-Reviewed Original ResearchMeSH KeywordsAgedAtrial FibrillationCatheter AblationFemaleHumansMedicareRisk FactorsTreatment OutcomeUnited StatesConceptsPrevious cardiac surgeryCardiac perforationAF ablationIntracardiac echocardiographyCardiac surgeryFemale sexDiagnosis of hemopericardiumPatient risk factorsSubset of patientsAtrial fibrillation ablationContemporary clinical practiceIntraprocedural intracardiac echocardiographyLogistic regression modelsCardiac tamponadeFatal complicationProcedural complicationsRare complicationCatheter ablationFibrillation ablationAtrial fibrillationModifiable factorsRisk factorsProcedural safetyRisk scoreLower risk
2019
Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation
Freeman JV, Shrader P, Pieper KS, Allen LA, Chan PS, Fonarow GC, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel JA, Singer DE, Go AS, Hylek EM, Steinberg BA, Peterson ED, Piccini JP. Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. Circulation Arrhythmia And Electrophysiology 2019, 12: e007612. PMID: 31830822, DOI: 10.1161/circep.119.007612.Peer-Reviewed Original ResearchConceptsAF catheter ablationOral anticoagulationRisk of strokeAF ablationCatheter ablationAntiarrhythmic medicationsDe novo AF ablationDiscontinuation of OACPropensity score-matched cohortAtrial fibrillation catheter ablationAF ablation patientsAnti-arrhythmic medicationsAtrial Fibrillation RegistryStroke prevention therapyBetter Informed TreatmentCohort of patientsPatterns of treatmentProportional hazards regressionUS national registryAnticoagulation useCause deathMajor bleedingSystemic embolismCardiovascular deathCause hospitalization
2018
Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF
Washam JB, Holmes DN, Thomas LE, Pokorney SD, Hylek EM, Fonarow GC, Mahaffey KW, Gersh BJ, Kowey PR, Ansell JE, Go AS, Reiffel JA, Freeman JV, Singer DE, Naccarelli G, Blanco R, Peterson ED, Piccini JP. Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF. Journal Of The American Heart Association 2018, 7: e008928. PMID: 30371218, PMCID: PMC6222961, DOI: 10.1161/jaha.118.008928.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAged, 80 and overAnti-Arrhythmia AgentsAnticoagulantsAtrial FibrillationDabigatranDrug Therapy, CombinationFemaleFollow-Up StudiesHumansMaleMiddle AgedProspective StudiesRegistriesRenal Insufficiency, ChronicRisk FactorsStrokeTime FactorsTreatment OutcomeWarfarinConceptsBackground Chronic kidney diseaseAntiarrhythmic drug useTransient ischemic attackChronic kidney diseaseAtrial fibrillationAdvanced CKDCKD statusIschemic attackSystemic embolismCause mortalityCreatinine clearanceRhythm controlKidney diseaseDrug useAtrial fibrillation scoreBaseline renal functionOral anticoagulant useRhythm control strategyCox proportional hazardsCKD patientsMajor bleedingOAC useCardiovascular deathCKD stageHigher CHAPrognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation
O'Brien EC, Holmes DN, Thomas LE, Fonarow GC, Allen LA, Gersh BJ, Kowey PR, Singer DE, Ezekowitz MD, Naccarelli GV, Ansell JE, Chan PS, Mahaffey KW, Go AS, Freeman JV, Reiffel JA, Peterson ED, Piccini JP, Hylek EM. Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. Circulation 2018, 138: 889-897. PMID: 29678813, DOI: 10.1161/circulationaha.117.031354.Peer-Reviewed Original ResearchConceptsStroke/systemic embolismMajor bleedingOral anticoagulantsAtrial fibrillationMinor bleeding eventsSubset of patientsVASc risk scorePooled logistic regressionYears of ageBleeding eventsEligible followOAC discontinuationOAC therapyOutpatient registrySystemic embolismAnticoagulated patientsMinor bleedingMedian ageTreatment satisfactionPrognostic significanceNuisance bleedingMedical recordsORBIT-AFIncidence ratePatient visitsCharacteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation
Durheim MT, Holmes DN, Blanco RG, Allen LA, Chan PS, Freeman JV, Fonarow GC, Go AS, Hylek EM, Mahaffey KW, Pokorney SD, Reiffel JA, Singer DE, Peterson ED, Piccini JP. Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. Heart 2018, 104: 1850. PMID: 29875139, DOI: 10.1136/heartjnl-2017-312735.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAnti-Arrhythmia AgentsAnticoagulantsAtrial FibrillationComorbidityFemaleHealth StatusHeart Conduction SystemHemorrhageHospitalizationHumansLungMalePrevalencePulmonary Disease, Chronic ObstructiveQuality of LifeRegistriesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited StatesConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseAtrial fibrillationSymptom burdenHeart failurePulmonary diseaseHigh riskDiagnosis of COPDNew-onset heart failureTreatment of AFBeta-blocker useCardiovascular risk factorsMajor bleeding eventsHigh symptom burdenBetter Informed TreatmentCoronary artery diseaseOutcomes of adultsQuality of lifeBleeding eventsDigoxin useBlocker useCause mortalityProspective registryReversible causesCardiovascular mortalityUnderuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review
Hsu JC, Freeman JV. Underuse of Vitamin K Antagonist and Direct Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A Contemporary Review. Clinical Pharmacology & Therapeutics 2018, 104: 301-310. PMID: 29328506, DOI: 10.1002/cpt.1024.Peer-Reviewed Original ResearchConceptsAtrial fibrillationStroke preventionVitamin K antagonistsDirect oral anticoagulantsNonvalvular AF patientsOral anticoagulant therapyRisk of strokeSpecial patient populationsSerious clinical problemOAC therapyK antagonistsOral anticoagulantsAnticoagulant therapyAF patientsPatient populationLeading causeClinical problemPatientsSignificant deleterious impactPreventionFibrillationTherapyContemporary reviewStrokeUnderuse
2017
Contemporary Procedural Complications, Hospitalizations, and Emergency Visits After Catheter Ablation for Atrial Fibrillation
Freeman JV, Tabada GH, Reynolds K, Sung SH, Liu TI, Gupta N, Go AS. Contemporary Procedural Complications, Hospitalizations, and Emergency Visits After Catheter Ablation for Atrial Fibrillation. The American Journal Of Cardiology 2017, 121: 602-608. PMID: 29331355, PMCID: PMC5805603, DOI: 10.1016/j.amjcard.2017.11.034.Peer-Reviewed Original ResearchConceptsAF ablationProcedural complicationsEmergency visitsAtrial flutterEmergency departmentRisk factorsLarge integrated health care delivery systemIntegrated health care delivery systemPrevious community-based studiesAcute inpatient complicationsAF ablation patientsEmergency department evaluationAortic valvular diseaseAtrial fibrillation ablationMultivariable logistic regressionStrong risk factorCommunity-based studyHealth care delivery systemInpatient complicationsAcute complicationsVascular complicationsAblation patientsAdult patientsCommon complicationDepartment evaluationLong-term morbidity and mortality after implantable cardioverter-defibrillator implantation with procedural complication: A report from the National Cardiovascular Data Registry
Kipp R, Hsu JC, Freeman J, Curtis J, Bao H, Hoffmayer KS. Long-term morbidity and mortality after implantable cardioverter-defibrillator implantation with procedural complication: A report from the National Cardiovascular Data Registry. Heart Rhythm 2017, 15: 847-854. PMID: 28987459, DOI: 10.1016/j.hrthm.2017.09.043.Peer-Reviewed Original ResearchConceptsCause mortalityMedicare beneficiariesICD implantationProcedural complicationsHospital characteristicsMultivariable Cox proportional hazards regression analysisNational Cardiovascular Data Registry ICD RegistryCox proportional hazards regression analysisFirst-time ICD recipientsImplantable cardioverter defibrillator implantationNational Cardiovascular Data RegistryProportional hazards regression analysisKaplan-Meier survival analysisLong-term morbidityPredictors of mortalityCardioverter-defibrillator implantationOccurrence of complicationsRetrospective registry studyAcute procedural complicationsHazards regression analysisLong-term outcomesRisk of mortalityMortality 3 yearsIndex hospitalizationRegistry studyOral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation
Black‐Maier E, Kim S, Steinberg BA, Fonarow GC, Freeman JV, Kowey PR, Ansell J, Gersh BJ, Mahaffey KW, Naccarelli G, Hylek EM, Go AS, Peterson ED, Piccini JP, Investigators F. Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. Clinical Cardiology 2017, 40: 746-751. PMID: 28543401, PMCID: PMC5638096, DOI: 10.1002/clc.22726.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAged, 80 and overAnticoagulantsAtrial FibrillationCardiac Pacing, ArtificialCardiac Resynchronization TherapyCardiac Resynchronization Therapy DevicesDefibrillators, ImplantableDrug Administration ScheduleDrug SubstitutionElectric CountershockFemaleHemorrhageHumansMaleMiddle AgedPacemaker, ArtificialRegistriesRisk FactorsStrokeTime FactorsTreatment OutcomeConceptsCardiac implantable electronic device implantationCIED implantationNOAC patientsAnticoagulation managementAF patientsAtrial fibrillationDevice implantationOral anticoagulation managementHigher creatinine clearanceManagement of anticoagulationOral anticoagulation therapyBetter Informed TreatmentOral anticoagulant therapyAtrial fibrillation patientsValvular heart diseaseBridging anticoagulationConcomitant aspirinInterrupted warfarinOAC therapyAnticoagulation strategiesAnticoagulation therapyOral anticoagulantsPeriprocedural riskAdverse eventsAnticoagulant therapy
2015
Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT‐AF Registry
Jackson LR, Kim SH, Piccini JP, Gersh BJ, Naccarelli GV, Reiffel JA, Freeman J, Thomas L, Chang P, Fonarow GC, Go AS, Mahaffey KW, Peterson ED, Kowey PR. Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT‐AF Registry. Clinical Cardiology 2015, 39: 119-125. PMID: 26720750, PMCID: PMC4784163, DOI: 10.1002/clc.22504.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAtrial FibrillationChi-Square DistributionComorbidityDisease ProgressionFemaleHumansLogistic ModelsMaleOdds RatioProportional Hazards ModelsProspective StudiesQuality of LifeRegistriesRisk AssessmentRisk FactorsSeverity of Illness IndexSick Sinus SyndromeTime FactorsTreatment OutcomeUnited StatesConceptsSinus node dysfunctionPermanent atrial fibrillationHigh symptom burdenAtrial fibrillationRisk-adjusted outcomesSymptom burdenTreatment patternsComorbid medical illnessesOutcomes of patientsAdverse cardiovascular outcomesParoxysmal atrial fibrillationPersistent atrial fibrillationORBIT-AF registryAF management strategyLogistic regression analysisCardiovascular outcomesComorbid illnessesAtrial tachyarrhythmiasMedical illnessHigh riskSevere symptomsPatientsDysfunctionOutcomesRegression analysisHeart rate is associated with progression of atrial fibrillation, independent of rhythm
Holmqvist F, Kim S, Steinberg BA, Reiffel JA, Mahaffey KW, Gersh BJ, Fonarow GC, Naccarelli GV, Chang P, Freeman JV, Kowey PR, Thomas L, Peterson ED, Piccini JP. Heart rate is associated with progression of atrial fibrillation, independent of rhythm. Heart 2015, 101: 894. PMID: 25732748, PMCID: PMC4453487, DOI: 10.1136/heartjnl-2014-307043.Peer-Reviewed Original ResearchConceptsAtrial fibrillationAF progressionHeart rateBaseline ECGRhythm control strategyBetter Informed TreatmentPredictors of progressionPersistent atrial fibrillationModest discriminatory powerLower heart rateHigher heart rateMore comorbiditiesOutcomes RegistryPatientsClinical practiceInformed TreatmentProgressionStrongest predictorFibrillationPredictorsBaselineAgeECGSustained formsSignificant interactionImpact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation—Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Holmqvist F, Guan N, Zhu Z, Kowey PR, Allen LA, Fonarow GC, Hylek EM, Mahaffey KW, Freeman JV, Chang P, Holmes DN, Peterson ED, Piccini JP, Gersh BJ, Investigators O. Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation—Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). American Heart Journal 2015, 169: 647-654.e2. PMID: 25965712, DOI: 10.1016/j.ahj.2014.12.024.Peer-Reviewed Original ResearchConceptsObstructive sleep apneaBetter Informed TreatmentAtrial fibrillationOutcomes RegistrySleep apneaHigh riskStroke/transient ischemic attackContinuous positive airway pressure (CPAP) treatmentContinuous positive airway pressure therapyPrevalence of OSAInformed TreatmentImpact of OSAPositive airway pressure therapyPositive airway pressure treatmentAF progression rateHierarchical logistic regression modelingMajor cardiovascular outcomesRhythm control therapyAirway pressure therapyTransient ischemic attackLong-term outcomesRisk of deathLogistic regression modelingMore persistent formsCV death